Nrx Pharmaceuticals (NRXP) Stock
Small pharmaceutical company developing new drug treatments. Here's the price, business snapshot, and what's worth knowing about Nrx Pharmaceuticals in October 2026.
NRX Pharmaceuticals Inc (NRXP) is a small-cap pharmaceutical company with a market capitalisation of roughly $76.3 million. As with many firms in this sector, NRX may focus on developing or licensing drug candidates rather than generating large commercial revenues today. Investors should know that small-cap biopharma stocks are often driven by clinical or regulatory milestones, partnerships and fundraising activity, which can create sharp share price moves in either direction. Key considerations include the company’s cash runway, the stage of any programmes, intellectual property and potential partners. Because such companies typically carry higher operational and clinical risk, performance can be volatile and future returns are uncertain. This summary is for general educational purposes only and not personal investment advice; suitability depends on an investor’s time horizon, risk tolerance and financial situation.
Nrx Pharmaceuticals (NRXP) Stock Forecast
Analyst price target, next 12 months
$34.00
+1070.4% vs today's $2.91
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Nrx Pharmaceuticals have a consensus 12-month target of $34.00, above the current price of $2.91.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying NRX Pharmaceuticals stock with a target price of $34, indicating strong growth potential.
Financial Health
NRX Pharmaceuticals is performing well with decent revenue, profit margins, and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Catalysts and Milestones
Clinical readouts, regulatory steps or partnership deals can move the stock materially, though outcomes are uncertain and may increase volatility.
Funding and Runway
Small biotechs often rely on capital markets or partners to fund development; check cash runway and potential dilution risks before investing.
Industry Context
Trends in regulation, competitor progress and licensing opportunities affect prospects, but therapeutic development timelines and outcomes can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
